No Data
Express News | eyebright medical technology (beijing) co., ltd. receives outstanding board of directors' best practice case of a listed company in 2024
Eyebright Medical Technology (Beijing) Co., Ltd. (688050): The price difference of artificial crystal channel inventory is almost replenished, and the profitability potential of the vision health business has improved.
In the third quarter of 2024, the company's revenue was 0.39 billion yuan (+49.11% year-on-year), net income attributable to the parent company was 0.11 billion yuan (+23.38% year-on-year), and net income attributable to non-controlling interests was 0.105 billion yuan (+
Eyebright Medical Technology (Beijing) Co., Ltd. (688050): Q3 revenue continues high growth momentum, private placement expands soft mirror production capacity.
Event: On October 29, 2024, eyebright medical technology (beijing) co., ltd. released the Q3 2024 quarterly report. From Q1 to Q3 2024, the company achieved revenue of 1.075 billion yuan (+60.94%), net income attributable to the parent company was 0.318 billion yuan (+26.0%).
eyebright medical technology (beijing) co., ltd. (688050): steady performance growth, additional capital increase in the beauty contact lens business
The company released its third quarter report for 2024. In the first three quarters of 2024, the company achieved total operating income of 1.075 billion yuan (+60.94% year-on-year) and net income attributable to the parent company of 0.318 billion yuan (+26.04% year-on-year).
Eyebright Medical Technology (Beijing) Co., Ltd. (688050) Third Quarter Report Review: Performance meets expectations, acceleration of performance next year can be expected.
Investment highlights: In the announcement, the company achieved total operating income of 1.075 billion yuan in the first three quarters of 2024 (+60.94%, representing the year-on-year growth rate, the same below), net income attributable to the mother 0.318 billion yuan (+26.04%).
688050 Aibo Healthcare 2024 Third Quarter Report
No Data
No Data